Dosage forms of mirdametinib
AssigneeSpringworks Therapeutics, Inc.
InventorsPiero L. RUGGIERO, Kristin PATTERSON, Mark HATCHER, Jiping LIU, Uchenna H. ILOEJE, Abraham J. LANGSETH
Life of this patent
Estimating the term…
Loading patent…
AssigneeSpringworks Therapeutics, Inc.
InventorsPiero L. RUGGIERO, Kristin PATTERSON, Mark HATCHER, Jiping LIU, Uchenna H. ILOEJE, Abraham J. LANGSETH
Estimating the term…
The present disclosure relates to an oral dosage form, such as a capsule, comprising (a) mirdametinib having a d90 no more than 250 microns, a d50 no more than 50 microns, or both, and (b) one or more pharmaceutically acceptable excipients. These dosage forms are useful in the treatment of tumors and cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), high grade glioma (HGG), low grade ovarian cancer, Langerhans cell histiocytosis (LCH), brain cancer, and a cancer that has metastasized to a patient's brain. The disclosure also related to improved dosage regimens for mirdametinib treatments.
An oral dosage form comprising (a) 0.5, 1, or 2 mg mirdametinib having a d50 of 1 to 30 microns and (b) one or more pharmaceutically acceptable excipients.
(canceled)
(canceled)
(canceled)
19-21. (canceled)
23-26. (canceled)
31-41. (canceled)
45-48. (canceled)
Dependencies are inferred from the claim text.